New insights into combinational drug therapy to manage congestion in heart Failure

Current Heart Failure Reports

Volumn 11, Issue 1, 2014, Pages 1-9

  Verbrugge, Frederik Hendrik ^a,b   Grieten, Lars ^a,b   Mullens, Wilfried ^a,b  

^a DEPARTMENT OF CARDIOLOGY   (Belgium)

^b HASSELT UNIVERSITY   (Belgium)

Author keywords

Acute decompensated heart failure; Congestion; Diuretics; Heart failure; Mineralocorticoid receptor antagonists; Natriuresis; Natriuretic peptides; Nesiritide; Neurohumoral blockers; Oral sodium binders; Pharmacologic therapy; Serelaxin; Sodium; Vasodilators; Vasopressin antagonists

Indexed keywords

ACETAZOLAMIDE; LOOP DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; NATRIURETIC FACTOR; NEURON BLOCKING AGENT; SERELAXIN; THIAZIDE DIURETIC AGENT; VASODILATOR AGENT; VASOPRESSIN ANTAGONIST;

ARTICLE; CARDIOMEGALY; CONGESTIVE HEART FAILURE; DIURETIC THERAPY; DRUG COMBINATION; EXTRACELLULAR SPACE; FOOD; HEART AUSCULTATION; HEMODYNAMIC MONITORING; HOSPITAL ADMISSION; HUMAN; HYPERVOLEMIA; LUNG EXTRAVASCULAR FLUID; NON INVASIVE PROCEDURE; PHENOTYPE; PHYSICAL DISEASE BY BODY FUNCTION; PULMONARY ARTERY OCCLUSION PRESSURE; SALT INTAKE; SODIUM BALANCE; SODIUM INTAKE; SODIUM RESTRICTION; TISSUE DOPPLER IMAGING;

CARDIOVASCULAR AGENTS; DRUG THERAPY, COMBINATION; HEART FAILURE; HUMANS; MINERALOCORTICOID RECEPTOR ANTAGONISTS; NATRIURESIS; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; VASODILATOR AGENTS; VASOPRESSINS;

EID: 84896711652     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-013-0174-4     Document Type: Article

References (70)

1. Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation. 2013;127:e6-245.
2. Adams Jr. KF, Fonarow GC, Emerman CL, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J. 2005;149:209-16. (Pubitemid 40348525)
3. • Dupont M, Mullens W, Tang WH. Impact of systemic venous congestion in heart failure. Curr Heart Fail Rep. 2011;8:233-41. A thorough review on the pathophysiology of congestion in heart failure.
4. Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO. Rehospitalization for heart failure: problems and perspectives. J Am Coll Cardiol. 2013;61:391-403.
5. Stevenson LW, Perloff JK. The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA. 1989;261:884-8. (Pubitemid 19046417)
6. Adamson PB, Magalski A, Braunschweig F, et al. Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J Am Coll Cardiol. 2003;41:565-71. (Pubitemid 36223320)
7. Zile MR, Bennett TD, St John Sutton M, et al. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation. 2008;118:1433-41.
8. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-7. (Pubitemid 34764819)
9. van Veldhuisen DJ, Linssen GC, Jaarsma T, et al. B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction. J Am Coll Cardiol. 2013;61:1498-506.
10. Kim HN, Januzzi Jr. JL. Natriuretic peptide testing in heart failure. Circulation. 2011;123:2015-9.
11. Shah MR, Hasselblad V, Tasissa G, et al. Rapid assay brain natriuretic peptide and troponin I in patients hospitalized with decompensated heart failure (from the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness Trial). Am J Cardiol. 2007;100:1427-33. (Pubitemid 47576023)
12. Binanay C, Califf RM, Hasselblad V, et al. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005;294:1625-33. (Pubitemid 41407355)
13. • Abraham WT, Adamson PB, Bourge RC, et al. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial. Lancet. 2011;377:658-66. Pivotal study demonstrating that improving the early detection of emerging congestion as pulmonary artery pressure elevations potentially reduces hospital readmissions for acute decompensated heart failure.
14. Steimle AE, Stevenson LW, Chelimsky-Fallick C, et al. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. Circulation. 1997;96:1165-72. (Pubitemid 27344219)
15. Mullens W, Abrahams Z, Francis GS, et al. Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol. 2008;52:200-7. (Pubitemid 351915785)
16. Mullens W, Abrahams Z, Francis GS, et al. Usefulness of Isosorbide Dinitrate and Hydralazine as add-on therapy in patients discharged for advanced decompensated heart failure. Am J Cardiol. 2009;103:1113-9.
17. Mullens W, Borowski AG, Curtin RJ, et al. Tissue Doppler imaging in the estimation of intracardiac filling pressure in decompensated patients with advanced systolic heart failure. Circulation. 2009;119:62-70.
18. Yu CM, Wang L, Chau E, et al. Intrathoracic impedance monitoring in patients with heart failure: correlation with fluid status and feasibility of early warning preceding hospitalization. Circulation. 2005;112:841-8. (Pubitemid 41170070)
19. Amir O, Rappaport D, Zafrir B, Abraham WT. A novel approach to monitoring pulmonary congestion in heart failure: initial animal and clinical experiences using remote dielectric sensing technology. Congest Heart Fail. 2013;19:149-55.
20. van Veldhuisen DJ, Braunschweig F, Conraads V, et al. Intrathoracic impedance monitoring, audible patient alerts, and outcome in patients with heart failure. Circulation. 2011;124:1719-26.
21. Mullens W, Oliveira LP, Verga T, et al. Insights from internet-based remote intrathoracic impedance monitoring as part of a heart failure disease management program. Congest Heart Fail. 2010;16:159-63.
22. Marik PE, Baram M, Vahid B. Does central venous pressure predict fluid responsiveness? A systematic review of the literature and the tale of seven mares. Chest. 2008;134:172-8. (Pubitemid 352008780)
23. Chaudhry SI, Wang Y, Concato J, et al. Patterns of weight change preceding hospitalization for heart failure. Circulation. 2007;116:1549-54. (Pubitemid 47511418)
24. • Fallick C, Sobotka PA, Dunlap ME. Sympathetically mediated changes in capacitance: redistribution of the venous reservoir as a cause of decompensation. Circ Heart Fail. 2011;4:669-75. Provocative review that discusses and explores impaired venous capacitance and sympathetically mediated volume shifts from the abdominal compartment to the effective circulatory system as a potential cause for elevated cardiac filling pressures.
25. •• Verbrugge FH, Dupont M, Steels P, et al. Abdominal contributions to cardio-renal dysfunction in congestive heart failure. J Am Coll Cardiol. 2013;62:485-95. State-of-the-art review discussing the role of abdominal congestion in the pathophysiology of heart failure and cardio-renal syndrome. Potential new diagnostic and treatment strategies are proposed.
26. Mullens W, Abrahams Z, Skouri HN, et al. Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function? J Am Coll Cardiol. 2008;51:300-6.
27. Mullens W, Abrahams Z, Francis GS, et al. Prompt reduction in intra-abdominal pressure following large-volume mechanical fluid removal improves renal insufficiency in refractory decompensated heart failure. J Card Fail. 2008;14:508-14. (Pubitemid 352040863)
28. Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341:577-85. (Pubitemid 29384167)
29. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012;14:803-69.
30. Yancy CW, Jessup M, Bozkurt B, et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;128:e240-319.
31. Heywood JT, Fonarow GC, Yancy CW, et al. Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF. Circ Heart Fail. 2010;3:596-605.
32. Paterna S, Gaspare P, Fasullo S, et al. Normal-sodium diet compared with low-sodium diet in compensated congestive heart failure: is sodium an old enemy or a new friend? Clin Sci (Lond). 2008;114:221-30. (Pubitemid 351293997)
33. Paterna S, Parrinello G, Cannizzaro S, et al. Medium term effects of different dosage of diuretic, sodium, and fluid administration on neurohormonal and clinical outcome in patients with recently compensated heart failure. Am J Cardiol. 2009;103:93-102.
34. • Arcand J, Ivanov J, Sasson A, et al. A high-sodium diet is associated with acute decompensated heart failure in ambulatory heart failure patients: a prospective follow-up study. Am J Clin Nutr. 2011;93:332-7. Currently, the only study that prospectively assessed sodium intake in heart failure patients, demonstrating an elevated risk of rehospitalizations for acute decompensated heart failure with higher intake.
35. Cooper HA, Dries DL, Davis CE, et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation. 1999;100:1311-5. (Pubitemid 29440124)
36. Hasselblad V, Gattis Stough W, Shah MR, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail. 2007;9:1064-9. (Pubitemid 47451811)
37. Schnermann J. Juxtaglomerular cell complex in the regulation of renal salt excretion. Am J Physiol. 1998;274:R263-79.
38. Francis GS, Siegel RM, Goldsmith SR, et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med. 1985;103:1-6. (Pubitemid 15068490)
39. Gotsman I, Keren A, Lotan C, Zwas DR. Changes in uric acid levels and allopurinol use in chronic heart failure: association with improved survival. J Card Fail. 2012;18:694-701.
40. Testani JM, Coca SG, McCauley BD, et al. Impact of changes in blood pressure during the treatment of acute decompensated heart failure on renal and clinical outcomes. Eur J Heart Fail. 2011;13:877-84.
41. Dupont M, Mullens W, Finucan M, et al. Determinants of dynamic changes in serum creatinine in acute decompensated heart failure: the importance of blood pressure reduction during treatment. Eur J Heart Fail. 2013;15:433-40.
42. Uchida T, Yamanaga K, Nishikawa M, et al. Anti-aldosteronergic effect of torasemide. Eur J Pharmacol. 1991;205:145-50.
43. Goodfriend TL, Ball DL, Oelkers W, Bahr V. Torsemide inhibits aldosterone secretion in vitro. Life Sci. 1998;63:PL45-50. (Pubitemid 28305573)
44. Lopez B, Querejeta R, Gonzalez A, et al. Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol. 2004;43:2028-35. (Pubitemid 38686797)
45. Murray MD, Deer MM, Ferguson JA, et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med. 2001;111:513-20. (Pubitemid 33052348)
46. Cosin J, Diez J. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail. 2002;4:507-13. (Pubitemid 36564972)
47. Muller K, Gamba G, Jaquet F, Hess B. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV-efficacy and quality of life. Eur J Heart Fail. 2003;5:793-801. (Pubitemid 38198067)
48. •• McKie PM, Schirger JA, Costello-Boerrigter LC, et al. Impaired natriuretic and renal endocrine response to acute volume expansion in pre-clinical systolic and diastolic dysfunction. J Am Coll Cardiol. 2011;58:2095-103. Excellent study showing that natriuresis is impaired in preclinical heart failure with preserved, as well as reduced, ejection fraction, even before hemodynamics are disturbed or neurohumoral activation is present. This might imply that targeting sodium avidity early on at the level of the kidney is essential in the prevention of congestion.
49. Mullens W, Tang WH. The early intertwining of the heart and the kidney through an impaired natriuretic response to acute volume expansion. J Am Coll Cardiol. 2011;58:2104-5.
50. • Costanzo MR, Heywood JT, Massie BM, et al. A double-blind, randomized, parallel, placebo-controlled study examining the effect of cross-linked polyelectrolyte in heart failure patients with chronic kidney disease. Eur J Heart Fail. 2012;14:922-30. Interesting proof-of-concept study demonstrating that oral sodium binders might facilitate restoring a neutral sodium balance in patients with heart failure.
51. Fonarow GC, Corday E. Overview of acutely decompensated congestive heart failure (ADHF): a report from the ADHERE registry. Heart Fail Rev. 2004;9:179-85. (Pubitemid 40521279)
52. • Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797-805. Although the use of loop diuretics is almost ubiquitous in acute decompensated heart failure, this trial is one of the few that offers high-quality evidence regarding their use.
53. Kramer BK, Schweda F, Riegger GA. Diuretic treatment and diuretic resistance in heart failure. Am J Med. 1999;106:90-6. (Pubitemid 29077144)
54. Kim GH. Long-term adaptation of renal ion transporters to chronic diuretic treatment. Am J Nephrol. 2004;24:595-605. (Pubitemid 40187017)
55. Loon NR, Wilcox CS, Unwin RJ. Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int. 1989;36:682-9. (Pubitemid 19239561)
56. Knauf H, Mutschler E. Functional state of the nephron and diuretic dose-response-rationale for low-dose combination therapy. Cardiology. 1994;84 Suppl 2:18-26. (Pubitemid 24271137)
57. Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol. 2010;56:1527-34.
58. Knauf H, Mutschler E. Sequential nephron blockade breaks resistance to diuretics in edematous states. J Cardiovasc Pharmacol. 1997;29:367-72. (Pubitemid 27194723)
59. Andersen LJ, Norsk P, Johansen LB, et al. Osmoregulatory control of renal sodium excretion after sodium loading in humans. Am J Physiol. 1998;275:R1833-42.
60. Konstam MA, Gheorghiade M, Burnett Jr. JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA. 2007;297:1319-31. (Pubitemid 46513233)
61. Cotter G, Metzkor E, Kaluski E, et al. Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary oedema. Lancet. 1998;351:389-93. (Pubitemid 28064161)
62. O'Connor CM, Starling RC, Hernandez AF, et al. Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med. 2011;365:32-43.
63. Gottlieb SS, Stebbins A, Voors AA, et al. Effects of Nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND-HF. J Am Coll Cardiol. 2013;62:1177-83.
64. Mullens W, Verbrugge FH. Increasing diuresis in congestive heart failure: ready for prime time? J Am Coll Cardiol. 2013;62:1184-6.
65. Conrad KP. Emerging role of relaxin in the maternal adaptations to normal pregnancy: implications for preeclampsia. Semin Nephrol. 2011;31:15-32.
66. Teichman SL, Unemori E, Teerlink JR, et al. Relaxin: review of biology and potential role in treating heart failure. Curr Heart Fail Rep. 2010;7:75-82.
67. •• Teerlink JR, Cotter G, Davison BA, et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;381:29-39. Phase II trial of serelaxin in the treatment of acute decompensated heart failure. This trial is remarkable because it is the first trial in this setting to report a reduction in all-cause mortality, although this was not a primary outcome.
68. Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, et al. Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol. 2013;61:196-206.
69. Cohn JN, Franciosa JA. Vasodilator therapy of cardiac failure: (first of two parts). N Engl J Med. 1977;297:27-31. (Pubitemid 8114597)
70. Kalaitzidis RG, Karasavvidou D, Siamopoulos KC. Renal sympathetic denervation and renal physiology. Curr Clin Pharmacol. 2013;8:189-96.